Thin Film Drugs Market Growth, Top Key Players, Trend, Opportunities Forecast to 2027
The global thin film drugs market size is projected to reach USD 16.27 billion in 2028. Fortune Business Insights™ published this information in a new study, titled, “Thin Film Drugs Market, 2021-2028.” The study further mentions that the market stood at USD 7.35 billion in 2020. It is expected to showcase a CAGR of 10.5% in the forecast period between 2021-2028. The surging geriatric population across the globe is anticipated to affect growth positively. As per the United Nations, in 2017, the global old age population was 962 million. It is estimated to double by the end of 2050 and reach 2.1 billion. Hence, the prevalence of Alzheimer’s and Parkinson’s diseases will also increase rapidly, thereby accelerating the demand for thin film drugs.
please visit: https://www.fortunebusinessinsights.com/thin-film-drugs-market-104883
Fortune Business Insights™ listed the names of prominent thin film drug providers present in the global market. They are as follows:
- Pfizer, Inc.(U.S.)
- Allergan (Ireland)
- ZIM Laboratories Limited (India)
- Novartis AG (Switzerland)
- Aquestive Therapeutics (U.S.)
- Sumitomo Dainippon Pharma Co. Ltd. (Japan)
- IntelGenx Corp (Canada)
- Wolters Kluwer (Netherlands)
- XPhyto Pharma (Germany)
- Other Prominent Players
Development of Cannabis-based Drugs to Propel Growth
The rising technological advancements occurring in the field of drug delivery systems is set to spur the thin film drugs market growth in the upcoming years. Additionally, numerous start-up firms are investing in the development of cannabis-based drugs. XPhyto Pharma, for instance, is likely to create around 13 drugs by using the thin firm drug delivery method. In Europe, the study is in Phase II clinical trial as of February 2021. However, the lack of high investments in emerging economies may obstruct growth.
Segmentation-
Retail Pharmacy Segment to Dominate Backed by Easy Availability of Drugs
Our analysts have segmented the market on the basis of product, disease indication, distribution channels, and geography. By product, it is fragmented into transdermal film drugs and oral thin film (OTF) drugs.